Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galapagos Shelves Ulcerative Colitis Program After PhII Failure

This article was originally published in Scrip

Executive Summary

Danish firm Galapagos NV has dropped development of its GLPG1205 in ulcerative colitis after it failed a Phase IIa trial. The G-protein coupled receptor 84-targeting small molecule was not shown with statistical significance to be more efficacious than placebo in the company's ORIGIN study. Details of the trial results will be published later this year, the firm said.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064319

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel